Infectious Enteritis Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023 - 2028)

Infectious Enteritis Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023 - 2028)

The Infectious Enteritis Treatment market is anticipated to grow with a CAGR of nearly 4.9% during the forecast period.

The COVID-19 pandemic had a significant impact on the infectious enteritis market. According to an article published by Clinical Medicine in March 2022, acute gastrointestinal side effects were reported with COVID-19 infection and were estimated to affect around 17% of patients. According to an article published by the Harvard Gazette in November 2021, 60% of patients infected with SARS-CoV-2 also report gastrointestinal symptoms such as nausea, diarrhea, and stomach pain. With an increase in these intestinal enteritis symptoms, the demand for its treatment increase. Therefore, the increasing number of cases of COVID-19 further led to an increased number of cases of infectious enteritis, and thus the market witnessed considerable growth during the pandemic. However, the market is witnessing stabilized growth currently owing to the decrease in COVID-19 cases and the increase in these intestinal enteritis cases, and is expected to project a similar trend over the coming years as per the analysis.

Factors such as the rising population with irritable bowel syndrome (IBS) and diarrhea cases due to infectious enteritis and intensive research and development activities, and Increasing FDA approvals of infectious enteritis treatment drugs are expected to drive the growth of the market over the forecast period. For instance, according to an article published by the Middle East Journal of Digestive Diseases in July 2022, it was estimated that the incidence of IBS is 38.5 per 10,000 persons per year, and the prevalence has been reported to be 10-17% in the general population. Furthermore, according to an article published by BMC Medicine, in March 2022, IBS patients are subtyped based on bowel habit profile into diarrhea (IBS-D), constipation (IBS-C), mixed (IBS-M) or indeterminate, and approximately 10–20% of all cases develop after an episode of acute gastroenteritis. Thus, increase in the population with IBS and diarrhea cases due to infectious enteritis, the demand for its treatment increase, thereby driving the growth of the market over the forecast period.

Additionally, various initiatives taken by the key market players, such as product launches, mergers, acquisitions, and partnerships, are expected to boost the market's growth during the forecast period. For instance, in November 2021, an interdisciplinary panel of infectious disease clinicians and public health experts led by the Center for Disease Dynamics, Economics & Policy (CDDEP) and the Africa CDC released the first edition of the African Antibiotic Treatment Guidelines for Common Bacterial Infections and Syndromes. Such an initiative is expected to drive the growth of the market.

The factors mentioned above are expected to drive the market's growth worldwide. However, several adverse effects associated with the treatment of infectious enteritis and a lack of awareness among people in developing countries are expected to restrain the growth of the studied market over the forecast period.

Antibiotics are medicines that fight bacterial infections. These are effective against a wide variety of enteric infections in adults, including shigellosis, salmonellosis, typhoid fever, cholera, and many more. Factors such as the rising population with these infections due to infectious enteritis are expected to drive the market's growth. For instance, according to an article published by the National Library of Medicine, in April 2021, acute gastroenteritis (AGE) is one of the most common bacterial infectious diseases clinicians face in daily practice. Globally, bacterial enteric pathogens cause billions of infections yearly with tremendous morbidity. In the United States alone it is estimated that there are nearly 200 million cases of AGE annually. Thus with an increase in bacterial enteritis, the demand for antibiotics increases, thereby driving the growth of the market.

The companies actively participate in new product launch developments and collaborations to expand their footprint. For instance, in June 2022, Shionogi & Co., Ltd. and the Global Antibiotic Research and Development Partnership (GARDP) signed the execution of a license and technology transfer agreement and, with the Clinton Health Access Initiative (CHAI), a collaboration agreement that aims to significantly transform the landscape of access to antibiotics for countries around the world. Such development is expected to drive the growth of the market.

Thus, the factors mentioned above are likely to contribute to the segment's growth over the forecast period.

North America is expected to dominate the infectious enteritis treatment market, and it is mainly driven due to the increasing prevalence of pathogens causing infectious enteritis and growing investment in healthcare. For instance, according to the CDC updated in December 2022, it is estimated Salmonella bacteria causes about 1.35 million infections and 26,500 hospitalizations in the United States every year. Therefore, the growing incidence rate of salmonella bacteria among people is expected to increase the demand for effective treatment, fueling the target market growth in the studied period.

Furthermore, the United States holds the largest market share in the North American region owing to factors such as the presence of a large number of market players manufacturing medications for infectious enteritis. In addition to this, several market players are engaged in product launches, thereby contributing to the region's growth. For instance, in March 2021, Knight Therapeutics Inc. commercially launched IBSRELA (tenapanor), a first-in-class therapy for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults. Such development is expected to drive the regional growth over the forecast period.

As a result, all the aforementioned factors are likely to contribute to this region's strong growth over the forecast period.

The infectious enteritis treatment market is fragmented in nature due to the presence of several companies operating globally as well as regionally. The competitive landscape includes an analysis of a few international as well as local companies which hold the market shares and are well known, including Actelion Pharmaceuticals, BioGaia, Bristol-Myers Squibb, GlaxoSmithKline plc, Mayne Pharma, Novartis Pharmaceuticals, Pfizer Inc., Teva Pharmaceuticals, among others.

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support